Nomura Asset Management Co. Ltd. Has $36.83 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Nomura Asset Management Co. Ltd. lifted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 18.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 432,032 shares of the medical research company’s stock after buying an additional 68,673 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $36,831,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after buying an additional 365,581 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Edwards Lifesciences by 4.9% during the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after buying an additional 977,933 shares during the last quarter. Norges Bank acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth about $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares during the last quarter. Finally, Holocene Advisors LP raised its holdings in shares of Edwards Lifesciences by 0.9% in the 3rd quarter. Holocene Advisors LP now owns 4,746,694 shares of the medical research company’s stock valued at $369,150,000 after purchasing an additional 42,717 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the transaction, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,371,239.08. The trade was a 24.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 95,057 shares of company stock valued at $7,874,217 in the last three months. 0.31% of the stock is currently owned by company insiders.

Analyst Ratings Changes

EW has been the topic of a number of research analyst reports. Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. BTIG Research upped their target price on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a report on Friday, April 24th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $95.65.

Edwards Lifesciences Stock Up 2.1%

Edwards Lifesciences stock opened at $88.33 on Tuesday. The stock has a market cap of $50.86 billion, a P/E ratio of 46.98, a P/E/G ratio of 2.17 and a beta of 0.87. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $89.14. The company’s 50-day moving average price is $81.85 and its two-hundred day moving average price is $83.02.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.